Protagonist Therapeutics PTGX Q1 2025 earnings
Reported May 6, 2025 · Before market open
Revenue$28.3MBeat by $21.8M
EPS-$0.19Beat by $0.31
Revenue estimate$6.6M
EPS estimate-$0.50
Next report
Aug 5, 2026 (In 1 week)Revenue estimate$199.8M
EPS estimate$2.11
Financials
Q1 2025Valuation & ratios
Segments
By segment
Versus estimates
Revenue
Diluted EPS
Ask the moment Protagonist Therapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Protagonist Therapeutics report Q1 2025 earnings?
- Protagonist Therapeutics (PTGX) reported Q1 2025 earnings on May 6, 2025 before market open.
- What were Protagonist Therapeutics's Q1 2025 revenue and EPS?
- Protagonist Therapeutics reported revenue of $28.3M and eps of $-0.19 for Q1 2025.
- Did Protagonist Therapeutics beat estimates in Q1 2025?
- Revenue beat the consensus estimate of $6.6M by $21.8M. EPS beat the consensus estimate of $-0.50 by $0.31.
- How did Protagonist Therapeutics's Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 88.9% from $255.0M a year earlier.
- Where can I find Protagonist Therapeutics's Q1 2025 SEC filings?
- You can read the 10-Q periodic report (0001558370-25-006530) directly on SEC EDGAR. The filing index links above go to sec.gov.